Cure My Disease

Don't miss your cure!

 Log in / Sign up

Liver-Friendly lymphoma treatment? new drug dosing study offers hope

NCT ID NCT05660395

Terminated Disease control Sponsor: ADC Therapeutics S.A. Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study tests the safety and best dose of loncastuximab tesirine, a targeted antibody-drug conjugate, in people with relapsed or refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma who also have moderate or severe liver impairment. The goal is to find a dosing regimen that works for these patients, who are often excluded from clinical trials. Only 5 participants are enrolled in this early-stage, open-label study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
loncastuximab tesirine (Zynlonta), an antibody-drug conjugate given by IV infusion
What this could lead to
If successful, this study could help determine safe and effective dosing of loncastuximab tesirine for lymphoma patients with liver problems, expanding treatment options for this group.
What could go wrong
This is a very early, small Phase 1b study with only 5 participants, so results may not apply broadly. Liver impairment can increase drug toxicity risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma high grade B-cell lymphoma lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B CELL LYMPHOMA HIGH GRADE B CELL LYMPHOMA

Contacts and locations

Locations

  • A Beneficência Portuguesa de São Paulo - Unidade Mirant

    São Paulo, 01323-030, Brazil

  • Albert Einstein Israelite Hospital

    São Paulo, 05652-900, Brazil

  • Dong-A University Hospital

    Pusan, Gyeongsangnam-do, 602-812, South Korea

  • Hospital 9 de Julho

    São Paulo, 01409-002, Brazil

  • Hospital Mãe de Deus - Centro Integrado de Oncologia

    Porto Alegre, 90110-270, Brazil

  • Hospital Sírio-Libanês - Brasília

    Brasília, 70200-730, Brazil

  • Hospital Sírio-Libanês - São Paulo

    São Paulo, 01308-050, Brazil

  • Koo Foundation Sun Yat-Sen Cancer Center

    Taipei, Taiwan 112, Taiwan

  • Korea University Anam Hospital

    Seoul, Seongbuk District, 02841, South Korea

  • Kyungpook National University Chilgok Hospital

    Daegu, Daegu Gwang'yeogsi, 41944, South Korea

  • National Taiwan University Hospital

    Taipei, 100, Taiwan

  • Seoul National University Hospital

    Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], 03080, South Korea

  • Severance Hospital

    Seoul, Seoul Teugbyeolsi, 03722, South Korea

  • The Oncology Institute of Hope & Innovation - Lynwood

    Lynwood, California, 90262, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.